Enadoline
From Wikipedia, the free encyclopedia
 |
|
|
Enadoline
|
|
| Systematic (IUPAC) name | |
| 2-(benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-
(pyrrolidin-1-yl)-1-oxaspiro[4.5] decan-8-yl)ethanamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C24H32N2O3 |
| Mol. mass | 396.52 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Enadoline is a drug which acts as a highly selective κ-opioid agonist.
In human studies, it produced visual distortions and feelings of dissociation, reminiscent of the effects of Salvinorin-A.[1]
It was looked at as a potential analgesic, but abandoned because of the dose-limiting effects of dysphoria, which could be expected from a κ-opioid agonist. There was mention of its potential in treating comatose head injury or stroke victims, where that type of side effect would be immaterial.[2]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
[edit] See also
[edit] References
- ^ Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001). "Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans". Psychopharmacology (Berl.) 157 (2): 151–62. PMID 11594439.
- ^ Barber A, Gottschlich R (1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opin Investig Drugs 6 (10): 1351–68. doi:. PMID 15989506.
|
|||||||||||
